Evidence map›Paper›PMID 26101704›Full record

ArticleAmerican journal of cancer research2015

MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2.

Yuqi He, Jianxun Wang, Jiheng Wang, Victoria Yee-Wa Yung, Emily Hsu, Aiqin Li, Qian Kang, Junbiao Ma, Qingfeng Han, Peng Jin and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Relationship betweenWorld journal of gastroenterology · 2018
    Article
  13. Article
  14. Article
  15. miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2).Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Yuqi HeDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
Jianxun WangInstitute for Translational Medicine, College of Medicine, Qingdao University Qingdao 266021, China.
Jiheng WangDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
Victoria Yee-Wa YungDepartment of Gastroenterology & Hepatology, University of California Davis, UC Davis Medical Center Sacramento, CA 95817.
Emily HsuDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles Los Angeles, CA 90095.
Aiqin LiDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
Qian KangDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
Junbiao MaDepartment of Coloproctology, The People's Hospital of Renqiu City Renqiu 062550, China.
Qingfeng HanDepartment of Coloproctology, The People's Hospital of Renqiu City Renqiu 062550, China.
Peng JinDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
Rui XingLaboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing, 100142, China.
Youyong LuLaboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing, 100142, China.
Jianqiu ShengDepartment of Gastroenterology, Beijing Military General Hospital Beijing 100700, China.
The Military General Hospital of Beijing PLA · CNMinistry of Education · ETShangqiu First People's Hospital · CNQingdao University · CNUniversity of California Davis Medical Center · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer remains the third most common cause of death from cancer worldwide. MicroRNA emerges as a good area of research for current cancer therapy. Here, we identified miR-135b to be a contributor to anti-apoptosis and chemoresistance in colorectal cancer. We observed high levels of miR-135b in colorectal cancer cell lines and clinical tissues, compared to colorectal epithelium cell line and noncancerous tissues. Furthermore, enforced expression of miR-135b attenuated doxorubicin-induced apoptosis in colorectal cells. (Doxorubicin alone can trigger significant apoptosis). In elucidating the molecular mechanism by which miR-135b participate in the regulation of apoptosis and chemoresistance in colorectal cancer, we discovered that large tumor suppressor kinase 2 (LATS2) is a direct target of miR-135b. The role of miR-135b was confirmed in colorectal tumor xenograft models. The growth of established tumors was suppressed by an inhibition of miR-135b expression and enhanced apoptosis was further assessed by TUNEL assay. Taken together, our results reveal that miR-135b and LATS2 axis may be a novel therapeutic target for colorectal cancer.

Indexed as

chemoresistancecolorectal cancerLATS2miR-135b

Identifiers

PMID26101704
PMCPMC4473317
OpenAlexW2464016809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.